Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Bone Marrow Transplant ; 30(4): 207-14, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12203136

ABSTRACT

The aim of this pilot study was to exploit the graft-versus-tumor potential of allogeneic transplants while improving safety of the procedure. Twelve patients with advanced hematological malignancies and solid tumors underwent a low intensity conditioning regimen (fludarabine and cyclophosphamide) followed by an allogeneic peripheral blood stem cell transplantation. The median time to achieve an absolute neutrophil count of more than 0.5 x 10(9)/l and an untransfused platelet count of more than 20 x 10(9)/l was 15 and 14 days, respectively. The main extra-hematological toxicities were mucositis and infections. Acute graft-versus-host (GVHD) disease was experienced by 62% of evaluable patients (grade II/B or III/C 80%) responsive to steroids. Extensive chronic GVHD was observed in 62% of patients. Non-relapse transplant-related mortality by day +30 was observed in three patients (25%). Eight out of 12 patients were full donor chimeric by day +100. One patient showed a mixed chimerism at day +37 when he died from progressive disease. One patient was in complete remission (CR) before allogeneic transplantation, and after transplantation four patients achieved CR and four experienced progressive disease. Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients.


Subject(s)
Granulocyte Colony-Stimulating Factor/administration & dosage , Immunosuppressive Agents/administration & dosage , Lymphoma/therapy , Neoplasms/therapy , Peripheral Blood Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Vidarabine/analogs & derivatives , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Cyclophosphamide/administration & dosage , Female , Graft Survival , Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Mobilization/methods , Humans , Immunosuppressive Agents/toxicity , Lymphoma/mortality , Male , Middle Aged , Neoplasms/mortality , Peripheral Blood Stem Cell Transplantation/adverse effects , Peripheral Blood Stem Cell Transplantation/mortality , Pilot Projects , Recombinant Proteins , Survival Analysis , Transplantation Conditioning/mortality , Transplantation, Homologous/adverse effects , Transplantation, Homologous/methods , Vidarabine/administration & dosage
2.
Bone Marrow Transplant ; 28(10): 923-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11753545

ABSTRACT

The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens +/- radiotherapy. The target yield was > or =3 x 10(6) CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifos- famide/vinorelbine and IGEV regimens. The median number of CD34+ cells/kg body weight collected was 10.9 x 10(6) (range 1.76-61.1 x 10(6)). The median total CD34+ cell/microl, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/microl, 10 x 10(4)/kg, and 17 900/microl, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Hematopoietic Stem Cell Mobilization/methods , Ifosfamide/pharmacokinetics , Lymphoma/drug therapy , Vinblastine/analogs & derivatives , Vinblastine/pharmacokinetics , Adult , Aged , Antigens, CD34/analysis , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization/standards , Humans , Ifosfamide/administration & dosage , Ifosfamide/toxicity , Leukapheresis/methods , Leukapheresis/standards , Leukocyte Count , Lymphoma/complications , Male , Middle Aged , Therapeutic Equivalency , Treatment Outcome , Vinblastine/administration & dosage , Vinblastine/toxicity , Vinorelbine
4.
Blood ; 89(1): 191-200, 1997 Jan 01.
Article in English | MEDLINE | ID: mdl-8978292

ABSTRACT

Seven of 112 hemophiliacs infected with human immunodeficiency virus type-1 (HIV-1) before 1986 through contaminated plasma products are currently healthy, with CD4 T-cell counts above 500 cells/microL, and have never received antiretroviral therapy (long-term nonprogressors [LTNPs]). Seven age and sex-matched hemophiliacs infected in the same period but who have progressive HIV disease (progressors) and one additional slow-progressing individual were also studied. One hundred-fold, 20-fold, and 10-fold lower levels of full-length HIV RNA in plasma, peripheral blood mononuclear cells (PBMCs), and proviral DNA in PBMCs, respectively, were found in LTNPs compared with progressors. Plasma and cell-associated HIV RNA and proviral DNA were lower in LTNPs who tested negative for viral isolation from PBMCs or who were positive only after removal of CD8+ cells. No substantial differences were observed in the in vitro production of chemokines including RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, and interleukin-8 (IL-8) in supernatants of activated PBMCs or CD8-depleted PBMCs of LTNPs, even when HIV isolation was simultaneously accomplished exclusively after removal of CD8+ cells. Low levels of HIV load and replication in peripheral blood are the strongest correlates of nonprogression in this small number of infected hemophiliacs.


Subject(s)
HIV Infections/complications , Hemophilia A/complications , Adolescent , Adult , CD4 Lymphocyte Count , Case-Control Studies , Chemokines/biosynthesis , Cohort Studies , DNA, Viral/isolation & purification , Disease Progression , HIV Infections/virology , HIV-1/isolation & purification , HIV-1/physiology , Humans , Leukocytes, Mononuclear/virology , Male , Middle Aged , Phenotype , Plasma/virology , Proviruses/isolation & purification , RNA, Viral/blood , Retrospective Studies , Survivors , T-Lymphocytes, Regulatory/immunology , Time Factors , Viremia/virology , Virus Cultivation , Virus Replication
6.
Ann Intern Med ; 121(6): 423-9, 1994 Sep 15.
Article in English | MEDLINE | ID: mdl-8053616

ABSTRACT

OBJECTIVE: To determine the effect of interferon-alpha for severe, zidovudine-resistant, HIV-1-related thrombocytopenia. DESIGN: Prospective, randomized, double-blind, placebo-controlled, multicenter, crossover trial. SETTING: Outpatient clinics in Central Northern Italy. PATIENTS: 15 sequential patients positive for HIV-1 with platelet counts less than 25 x 10(9)/L who were refractory to 1 month of full-dose (1000 mg/d) zidovudine. INTERVENTION: Interferon-alpha (3 million units) or placebo (1 mL saline) three times a week subcutaneously for 4 weeks, followed by a 4-week washout period. Patients were then switched to the alternative treatment for the next 4 weeks, followed by another 4 weeks of washout, and they were randomly assigned to either sequence of treatment. Patients received zidovudine (200 mg three times daily) throughout the study. MEASUREMENTS: The primary end point was the platelet count (measured weekly). Secondary end points were qualitative assessment of the platelet response; bleeding time; p24 antigen in serum; CD4/CD8 counts; beta 2-microglobulin in serum; and platelet-associated IgG. RESULTS: Interferon-alpha significantly increased platelet counts in the 12 patients who completed the study (baseline level, 15.6 +/- 7.1 x 10(9)/L; after 4 weeks of interferon-alpha therapy, 82.2 +/- 52.2 x 10(9)/L). The estimated increase in the platelet count after interferon-alpha compared with placebo was 60.0 x 10(9)/L (95% CI, 23.2 to 96.8 x 10(9)/L). The increase was already statistically significant after 3 weeks (66.6 +/- 49.7 x 10(9)/L) and remained significantly increased 1 week after discontinuing interferon-alpha therapy (58.2 +/- 45.0 x 10(9)/L). Placebo did not modify the platelet count. The bleeding time was significantly shortened by interferon-alpha. Four of 12 patients who had more serious alterations of some measures reflecting disease severity did not respond to interferon-alpha. No relevant side effects were observed. CONCLUSIONS: Interferon-alpha is a safe and effective treatment for zidovudine-resistant, HIV-related thrombocytopenia.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , HIV-1 , Interferon-alpha/therapeutic use , Thrombocytopenia/therapy , Adult , Bleeding Time , Double-Blind Method , Female , Humans , Interferon-alpha/adverse effects , Male , Platelet Count , Prospective Studies , Thrombocytopenia/blood , Thrombocytopenia/etiology , Zidovudine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...